Raymond James Financial
DNTH icon

Raymond James Financial’s Dianthus Therapeutics DNTH Stock Holding History

Raymond James Financial’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Sell
4,338
-10,750
-71% -$939K ﹤0.01% 4624
2026
Q1 		$1.27M Buy
+15,088
New +$874K ﹤0.01% 3694
2025
Q4 		– Sell
-11,245
Closed -$442K – 5205
2025
Q3 		$442K Buy
11,245
+9,815
+686% +$251K ﹤0.01% 4185
2025
Q2 		$26.6K Buy
+1,430
New +$26.8K ﹤0.01% 5468

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Raymond James Financial's DNTH Position: Q2 2026 in Review

Raymond James Financial reduced its Dianthus Therapeutics (DNTH) stake by 71% in Q2 2026, selling an estimated $939K and leaving 4,338 shares worth $423K. The position accounts for ﹤0.01% of the portfolio, ranked #4624.

Raymond James Financial first reported a position in DNTH in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.27M in Q1 2026. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Raymond James Financial held 4,338 shares of Dianthus Therapeutics worth $423K as of Q2 2026.
  • Raymond James Financial sold 10,750 Dianthus Therapeutics shares in Q2 2026, an estimated $939K.
  • Dianthus Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4624 holding.
  • Raymond James Financial first reported a position in Dianthus Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Raymond James Financial's Dianthus Therapeutics position peaked at $1.27M in Q1 2026.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.